Literature DB >> 2713252

Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.

P Lagarde1, F Bonichon, H Eghbali, I de Mascarel, J Chauvergne, B Hoerni.   

Abstract

From 1972 to 1976, 95 patients with clinical stages I-IIIA Hodgkin's disease were treated by chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) before and after extended field radiotherapy. The CVPP schedule gave: (1) a constant drug dosage for each patient independent of body surface or weight; and (2) a total drug dosage dependent on haematological tolerance, since the treatment was given for 21 days or until the leukocyte count dropped to 2 x 10(9) l-1. The drug dosage per unit body surface (or 'dose density') significantly correlates with the drop in leukocyte count (P less than 0.001) and the tumour regression at the end of the induction course (P = 0.020). Disease-free survival is significantly related to dose density (P = 0.050) but not to dose intensity calculated on the duration of treatment (P = 0.240). However, after exclusion of three marginal recurrences due to border-line radiotherapy, the dose intensity significantly correlates with the disease-free survival (P = 0.031) and with the duration of complete remission (r = 0.870).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2713252      PMCID: PMC2247159          DOI: 10.1038/bjc.1989.131

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  [Significance of chemotherapy complementary to radiotherapy in stages I and II in Hodgkin's disease].

Authors:  C Lagarde; J Chauvergne; M Durand; B Hoerni; G Hoerni-Simon; J Touchard
Journal:  Bull Cancer       Date:  1975 Jan-Mar       Impact factor: 1.276

2.  Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin's disease.

Authors:  C H Diggs; P H Wiernik; J A Levi; L K Kvols
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

3.  Combinaed chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for patients with advanced Hodgkin's disease. An alternative program to MOPP.

Authors:  C D Bloomfield; R B Weiss; I Fortuny; G Vosika; B J Kennedy
Journal:  Cancer       Date:  1976-07       Impact factor: 6.860

4.  Brief chemotherapy associated with extended field radiotherapy in Hodgkin's disease. Long-term results in a series of 102 patients with clinical stages I-IIIA.

Authors:  P Lagarde; H Eghbali; F Bonichon; I de Mascarel; J Chauvergne; B Hoerni
Journal:  Eur J Cancer Clin Oncol       Date:  1988-07

5.  [Common language for expression of therapeutic results in oncology].

Authors:  J Chauvergne; B Hoerni; M Durand
Journal:  Bull Cancer       Date:  1974 Apr-Jun       Impact factor: 1.276

6.  [Vinblastine + procarbazine + cyclophosphamide association in the treatment of Hodgkin's disease (author's transl)].

Authors:  J Chauvergne; B Hoerni; G Hoerni-Simon; M Durand; C Lagarde
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1973-11-01

7.  Clinical evaluation and radiotherapeutic management of Hodgkin's disease and the malignant lymphomas.

Authors:  H S Kaplan
Journal:  N Engl J Med       Date:  1968-04-18       Impact factor: 91.245

8.  Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease.

Authors:  J A Green; A A Dawson; L F Fell; S Murray
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

9.  Hodgkin's disease treated by chemotherapy and large field irradiation. Hematologic effects.

Authors:  H Eghbali; G Hoerni-Simon; M Durand; J Chauvergne; J Touchard; B Hoerni
Journal:  Acta Radiol Oncol Radiat Phys Biol       Date:  1978

10.  Combined chemotherapy cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) vs. CVPP plus CCNU (CCVPP) in Hodgin's disease.

Authors:  M Morgenfeld; N Somoza; J Magnasco; S Pavlovsky; A C de Bonesana; R Bezares; A Suárez; J Pileggi; J M Lein; A Macchi; S I Calabria; G E Garay; S C de Sica; S Besuschio
Journal:  Cancer       Date:  1979-05       Impact factor: 6.860

View more
  4 in total

Review 1.  Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. More is better, or is it?

Authors:  D J Dodwell; E S de Campos; J A Radford
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

2.  Novel combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP II) before radical radiotherapy in localized stages (I-IIIA) of Hodgkin's disease. Early results in 100 consecutive patients. Pierre-et-Marie-Curie Group.

Authors:  B Hoerni; M B Orgerie; H Eghbali; C M Blanc; B David; J Rojouan; R Zittoun
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 3.  Dose intensity in cancer chemotherapy.

Authors:  D J Dodwell; H Gurney; N Thatcher
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

4.  A trial of individual dose intensity and relative performance factors in tegafur maintenance chemotherapy for head and neck cancer.

Authors:  S Sawaki; H Watanabe; T Shin; T Kubota; S Komiyama; T Umezaki; I Nahm
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.